These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

629 related items for PubMed ID: 22123928

  • 1. Multiple sclerosis, natalizumab, and PML: helping patients decide.
    Rudick RA.
    Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S18-23. PubMed ID: 22123928
    [Abstract] [Full Text] [Related]

  • 2. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 3. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A.
    Neurology; 2012 May 29; 78(22):1736-42. PubMed ID: 22592369
    [Abstract] [Full Text] [Related]

  • 4. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
    Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T.
    Mult Scler; 2012 Feb 29; 18(2):143-52. PubMed ID: 22312009
    [Abstract] [Full Text] [Related]

  • 5. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.
    Tur C, Tintoré M, Vidal-Jordana A, Castilló J, Galán I, Río J, Arrambide G, Comabella M, Arévalo MJ, Horno R, Vicente MJ, Caminero A, Nos C, Sastre-Garriga J, Montalban X.
    Mult Scler; 2012 Aug 29; 18(8):1193-6. PubMed ID: 22383232
    [Abstract] [Full Text] [Related]

  • 6. Advances in the management of PML: focus on natalizumab.
    Fox R.
    Cleve Clin J Med; 2011 Nov 29; 78 Suppl 2():S33-7. PubMed ID: 22123933
    [Abstract] [Full Text] [Related]

  • 7. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
    Baldwin KJ, Hogg JP.
    Curr Opin Neurol; 2013 Jun 29; 26(3):318-23. PubMed ID: 23493158
    [Abstract] [Full Text] [Related]

  • 8. [[Natalizumab therapy, 2013].
    Karácsony M, Bencsik K, Vécsei L.
    Ideggyogy Sz; 2014 Jul 30; 67(7-8):220-8. PubMed ID: 25509362
    [Abstract] [Full Text] [Related]

  • 9. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ.
    Neurologist; 2006 Nov 30; 12(6):293-8. PubMed ID: 17122725
    [Abstract] [Full Text] [Related]

  • 10. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
    Reuwer AQ, Heron M, van der Dussen D, Schneider-Hohendorf T, Murk JL.
    Acta Neurol Scand; 2017 Nov 30; 136 Suppl 201():37-44. PubMed ID: 29068484
    [Abstract] [Full Text] [Related]

  • 11. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
    Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M.
    J Clin Virol; 2013 Jun 30; 57(2):141-6. PubMed ID: 23465394
    [Abstract] [Full Text] [Related]

  • 12. Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.
    Serana F, Chiarini M, Sottini A, Bertoli D, Giustini V, Tessitore MV, Caimi L, Capra R, Imberti L.
    J Neuroimmunol; 2014 Dec 15; 277(1-2):6-12. PubMed ID: 25468273
    [Abstract] [Full Text] [Related]

  • 13. The link between VLA-4 and JC virus reactivation.
    Monaco MC, Major EO.
    Expert Rev Clin Immunol; 2012 Jan 15; 8(1):63-72. PubMed ID: 22149341
    [Abstract] [Full Text] [Related]

  • 14. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
    Cutter GR, Stüve O.
    Mult Scler; 2014 Sep 15; 20(10):1304-5. PubMed ID: 24812045
    [Abstract] [Full Text] [Related]

  • 15. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.
    Mult Scler; 2013 Jun 15; 19(7):912-9. PubMed ID: 23232602
    [Abstract] [Full Text] [Related]

  • 16. Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients.
    Nali LH, Moraes L, Fink MC, Callegaro D, Romano CM, Oliveira AC.
    Arq Neuropsiquiatr; 2014 Dec 15; 72(12):960-5. PubMed ID: 25465776
    [Abstract] [Full Text] [Related]

  • 17. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.
    Planas R, Jelčić I, Schippling S, Martin R, Sospedra M.
    Eur J Immunol; 2012 Mar 15; 42(3):790-8. PubMed ID: 22144343
    [Abstract] [Full Text] [Related]

  • 18. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
    Carruthers RL, Chitnis T, Healy BC.
    Mult Scler; 2014 May 15; 20(6):757-60. PubMed ID: 24189572
    [Abstract] [Full Text] [Related]

  • 19. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.
    Hunt D, Giovannoni G.
    Pract Neurol; 2012 Feb 15; 12(1):25-35. PubMed ID: 22258169
    [Abstract] [Full Text] [Related]

  • 20. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.
    Villar LM, Costa-Frossard L, Masterman T, Fernandez O, Montalban X, Casanova B, Izquierdo G, Coret F, Tumani H, Saiz A, Arroyo R, Fink K, Leyva L, Espejo C, Simó-Castelló M, García-Sánchez MI, Lauda F, Llufriú S, Álvarez-Lafuente R, Olascoaga J, Prada A, Oterino A, de Andrés C, Tintoré M, Ramió-Torrentà L, Rodríguez-Martín E, Picón C, Comabella M, Quintana E, Agüera E, Díaz S, Fernandez-Bolaños R, García-Merino JA, Landete L, Menéndez-González M, Navarro L, Pérez D, Sánchez-López F, Serrano-Castro PJ, Tuñón A, Espiño M, Muriel A, Bar-Or A, Álvarez-Cermeño JC.
    Ann Neurol; 2015 Mar 15; 77(3):447-57. PubMed ID: 25581547
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.